AVIDITY BIOSC.INC.-,0001 Logo
US05370A1088

AVIDITY BIOSC.INC.-,0001

Ins Portfolio

Kurse werden geladen...

 Anzeige

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +56,87(+79,17%). Der Median liegt bei +56,87(+79,17%).

Kaufen
  8
Halten
  0
Verkaufen
  0

Scoring-Modelle

Dividenden-Strategie0 / 15
HGI-Strategie5 / 18
Levermann-Strategie-5 / 13
Powered byaktien.guide

News

  • Foto von Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO , Jan. 20, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted a non-qualified stock option award to purchase an aggregate of 10,500 shares of its common stock and 5,250 restricted stock units ("RSUs") to one (1) new non-executive employee under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).» Mehr auf prnewswire.com

  • Foto von Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO , Jan. 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 6, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted a non-qualified stock option award to purchase an aggregate of 80,000 shares of its common stock and 40,000 restricted stock units ("RSUs") to Charles Calderaro III, under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"), in connection with Mr. Calderaro's hiring and appointment as Avidity's Chief Technical Officer.» Mehr auf prnewswire.com

  • Foto von Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025

    Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025

    Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025   On track to complete enrollment in del-desiran HARBOR TM Phase 3 and potential registrational del-brax biomarker cohort as well as initiate global pivotal trial for del-brax by mid-2025    Eric Mosbrooker expands role to Chief Commercial Officer; Charles Calderaro III, Chief Technical Officer, and Kat Lange, Chief Business Officer, join as company prepares for global commercialization and continued pipeline expansion   Avidity to present at 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14 SAN DIEGO , Jan. 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its progress and planning for a transformational year in 2025.» Mehr auf prnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte AVIDITY BIOSC.INC.-,0001 einen Umsatz von +2,10 Mio und ein Nettoeinkommen von 72,19 Mio
(EUR)Sep. 2024
YOY
Umsatz+2,10 Mio21,20%
Bruttoeinkommen+2,10 Mio46,29%
Nettoeinkommen72,19 Mio45,97%
EBITDA87,48 Mio59,52%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+3,85 Mrd
Anzahl Aktien
119,31 Mio
52 Wochen-Hoch/Tief
+53,98 - +10,82
DividendenNein
Beta
0,91
KGV (PE Ratio)
14,74
KGWV (PEG Ratio)
7,25
KBV (PB Ratio)
+2,75
KUV (PS Ratio)
+395,24

Unternehmensprofil

Avidity Biosciences, Inc. ist ein biopharmazeutisches Unternehmen, das sich mit der Entwicklung von Therapien auf Oligonukleotidbasis befasst. Es entwickelt Antikörper-Oligonukleotid-Konjugate (AOC), die zur Behandlung einer Reihe schwerer Krankheiten bestimmt sind. Der führende Produktkandidat des Unternehmens, AOC 1001, wird zur Behandlung der myotonen Dystrophie Typ 1, einer seltenen monogenen Muskelerkrankung, eingesetzt; AOC 1044 zur Behandlung der Duchenne-Muskeldystrophie und AOC 1020 zur Behandlung der fazioskapulohumeralen Muskeldystrophie befinden sich im präklinischen Stadium. Das Unternehmen bietet auch die Lumizyme-Therapie für die Pompe-Krankheit an. Avidity Biosciences, Inc. wurde im Jahr 2012 gegründet und hat seinen Hauptsitz in San Diego, Kalifornien.

Name
AVIDITY BIOSC.INC.-,0001
CEO
Sarah Boyce
SitzSan Diego, ca
USA
Website
Industrie
Chemikalien
Börsengang
Mitarbeiter253

Ticker Symbole

BörseSymbol
NASDAQ
RNA

Assets entdecken

Shareholder von AVIDITY BIOSC.INC.-,0001 investieren auch in folgende Assets

🍪

Parqet nutzt Cookies.Erfahre Mehr